James Ford
Clinical Trials
- A Phase II Study of GSK1363089 (Formerly XL880) for Metastatic Gastric Cancer Recruiting
- Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma Recruiting
- Phase II Trial - Breast Cancer Chemoprevention by Lovastatin Recruiting
- Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer Recruiting
- Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia Recruiting
- Molecular Genetic and Pathological Studies of Anal Tumors Recruiting
- Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Recruiting
- PII Combination SBRT with TACE for Unresectable Hepatocellular Carcinoma Recruiting
- Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma Recruiting
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors Recruiting
- Phase II Gemcitabine, Carboplatin & PARP Inhibitor BSI-201 in Neoadjuvant Tx of Triple-Neg Breast CA Recruiting
- Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer No longer recruiting
- Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples Completed
- Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer No longer recruiting
- Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer No longer recruiting
- Safety Study of Cetuximab in combination with Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer Completed
- Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer Completed
Help
Trial Administration